An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
NCT01037179
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Sponsor
Alcon Research